Evidence map›Paper›PMID 31802967›Full record

ArticlePragmatic and observational research2019

Integrating Machine Learning With Microsimulation to Classify Hypothetical, Novel Patients for Predicting Pregabalin Treatment Response Based on Observational and Randomized Data in Patients With Painful Diabetic Peripheral Neuropathy.

Joe Alexander, Roger A Edwards, Luigi Manca, Roberto Grugni, Gianluca Bonfanti, Birol Emir, Ed Whalen, Steve Watt, Marina Brodsky, Bruce Parsons

4 registry-linked trialsOpen access · diamondAbstract read
In one paragraph

Article in Pragmatic and observational research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00143156 phase3completednot on this map

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial of Pregabalin Versus Placebo in the Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

TypeinterventionalSponsorPfizer's Upjohn has merged with Mylan to form Viatris Inc.Ran2005 to 2007Enrolled450ConditionsDiabetic NeuropathiesArmspregabalin
NCT00156078 phase4completednot on this map

A 14-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Pregabalin (150mg-600mg/Day) Using A Flexible Optimal Dose Schedule In Patients With Painful Diabetic Peripheral Neuropathy (DPN).

TypeinterventionalSponsorPfizer's Upjohn has merged with Mylan to form Viatris Inc.Ran2005 to 2007Enrolled450ConditionsDiabetic Neuropathy, PainfulArmspregabalin
NCT00159679 phase4completednot on this map

A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy

TypeinterventionalSponsorPfizer's Upjohn has merged with Mylan to form Viatris Inc.Ran2004 to 2005Enrolled167ConditionsDiabetic Neuropathy, PainfulArmsPregabalin
NCT00553475 phase3completednot on this map

Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate Efficacy And Safety Of Pregabalin (CI-1008) In The Treatment For Pain Associated With Diabetic Peripheral Neuropathy

TypeinterventionalSponsorPfizer's Upjohn has merged with Mylan to form Viatris Inc.Ran2007 to 2009Enrolled314ConditionsDiabetic Neuropathy, PainfulArmsplacebo, pregabalin
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Moving towards the use of artificial intelligence in pain management.European journal of pain (London, England) · 2025
    Pooled it
  2. Review
  3. Machine Learning in Pain Neuromodulation.Advances in experimental medicine and biology · 2024
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Joe Alexander *Global Medical Affairs, Pfizer Inc, New York, NY 10017, USA.
Roger A Edwards *Health Services Consulting Corporation, Boxborough, MA 01719, USA.
Luigi MancaFair Dynamics Consulting, SRL, Milan, Italy.ORCID 0000-0002-1301-0828
Roberto GrugniFair Dynamics Consulting, SRL, Milan, Italy.ORCID 0000-0003-0490-1896
Gianluca BonfantiFair Dynamics Consulting, SRL, Milan, Italy.
Birol EmirGlobal Statistics, Pfizer Inc, New York, NY 10017, USA.
Ed WhalenGlobal Statistics, Pfizer Inc, New York, NY 10017, USA.
Steve WattGlobal Medical Affairs, Pfizer Inc, New York, NY 10017, USA.
Marina BrodskyGlobal Medical Affairs, Pfizer Inc, Groton, CT 06340, USA.
Bruce ParsonsGlobal Medical Product Evaluation, Pfizer Inc, New York, NY 10017, USA.ORCID 0000-0002-4154-0308
Pfizer (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeVariability in patient treatment responses can be a barrier to effective care. Utilization of available patient databases may improve the prediction of treatment responses. We evaluated machine learning methods to predict novel, individual patient responses to pregabalin for painful diabetic peripheral neuropathy, utilizing an agent-based modeling and simulation platform that integrates real-world observational study (OS) data and randomized clinical trial (RCT) data. PATIENTS AND

methodsThe best supervised machine learning methods were selected (through literature review) and combined in a novel way for aligning patients with relevant subgroups that best enable prediction of pregabalin responses. Data were derived from a German OS of pregabalin (N=2642) and nine international RCTs (N=1320). Coarsened exact matching of OS and RCT patients was used and a hierarchical cluster analysis was implemented. We tested which machine learning methods would best align candidate patients with specific clusters that predict their pain scores over time. Cluster alignments would trigger assignments of cluster-specific time-series regressions with lagged variables as inputs in order to simulate "virtual" patients and generate 1000 trajectory variations for given novel patients.

resultsInstance-based machine learning methods (k-nearest neighbor, supervised fuzzy c-means) were selected for quantitative analyses. Each method alone correctly classified 56.7% and 39.1% of patients, respectively. An "ensemble method" (combining both methods) correctly classified 98.4% and 95.9% of patients in the training and testing datasets, respectively.

conclusionAn ensemble combination of two instance-based machine learning techniques best accommodated different data types (dichotomous, categorical, continuous) and performed better than either technique alone in assigning novel patients to subgroups for predicting treatment outcomes using microsimulation. Assignment of novel patients to a cluster of similar patients has the potential to improve prediction of patient outcomes for chronic conditions in which initial treatment response can be incorporated using microsimulation. CLINICAL TRIAL REGISTRIES: www.clinicaltrials.gov: NCT00156078, NCT00159679, NCT00143156, NCT00553475.

Indexed as

agent-based modeling and simulationcoarsened exact matchinghierarchical cluster analysismachine learningtime series regressions

Identifiers

PMID31802967
PMCPMC6827520
OpenAlexW2982689230

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.